Press Release issued Jan 13, 2021: Frontida BioPharm, Inc., a pharmaceutical Contract Development and Manufacturing Organization based in Philadelphia and Chicago areas, announced today the launch of its new Category 1 (CAT.ONETM) in vitro testing and evaluation services to support the development and regulatory approvals for abuse-deterrent formulations of pain management and Central Nervous System (CNS) targeted therapies.
Press ReleasesJanuary 14, 2021
Frontida BioPharm, Inc. Launches CAT.one Testing to Support Abuse-Deterrent Product Development
Frontida BioPharm, Inc. Announces Praful Agrawala, Ph.D., as Executive Vice President, Technology
December 1, 2020